Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
prinomastat · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| cisplatin | DRUG | - |
| gemcitabine hydrochloride | DRUG | - |
| prinomastat | DRUG | - |
| temozolomide | DRUG | - |
DISEASE CHARACTERISTICS: Stage IV or recurrent or T4 lesion non-small cell lung cancer Measurable or evaluable disease No brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: ...
Top 20 of 75 competitors
Prinomastat is an investigational small molecule drug that was studied in oncology for the treatment of brain and central nervous system tumors and lung cancer. It was developed by Pfizer, Inc. (ticker: PFE) and reached Phase 2 clinical development. It is not an approved therapy.
Prinomastat belongs to the -stat class of enzyme inhibitors. This target class describes drugs that inhibit enzymes, and prinomastat was developed within that class as a small molecule for oncology indications including brain and central nervous system tumors and lung cancer.
Prinomastat was developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the clinical research on the drug, including studies in brain and central nervous system tumors and in lung cancer.
Prinomastat is an investigational drug that reached Phase 2 clinical development. It is not approved, and no active trials are ongoing. The completed research included a Phase 2 study and a Phase 3 study, both of which have finished.
Prinomastat has been studied in completed clinical trials. NCT00004200 evaluated prinomastat plus temozolomide following radiation therapy in patients with newly diagnosed glioblastoma multiforme. NCT00004199 evaluated prinomastat with combination chemotherapy in patients with metastatic or recurrent non-small cell lung cancer. Both trials were conducted in the United States and have completed.
Prinomastat was studied in brain and central nervous system tumors, specifically in a Phase 2 trial of prinomastat plus temozolomide following radiation therapy in patients with newly diagnosed glioblastoma multiforme. That trial, NCT00004200, has completed. Prinomastat is investigational and is not an approved treatment.